Very recently, Castro et al. [29] demonstrated that targeting Ags to CD11c, the □-chain of CR4, on DCs exerted uniquely effective properties to generate both CD4+ and CD8+ T cell responses, and suggested CD11c targeting as efficient vaccination approach for protection against tumor development. Here, ITGAX is linked to neoplasm.